You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ophthalmic%20Solutions

Showing 1 - 25 of 2,869
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Eye Diseases, Presbyopia, Refractive Errors Trial in Newport Beach (Aceclidine + Brimonidine, Aceclidine)

Recruiting
  • Eye Diseases
  • +5 more
  • Newport Beach, California
    Site #101
Jul 7, 2023

Neurotrophic Keratitis Trial (BRM424 Ophthalmic Solution, Vehicle)

Not yet recruiting
  • Neurotrophic Keratitis
  • (no location specified)
Jun 28, 2023

Opthalomology/Dry Eye Trial in Milan, Pisa (Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil)

Recruiting
  • Opthalomology/Dry Eye
  • Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil
  • Milan, Italy
  • +1 more
Mar 17, 2023

Dry Eye Disease Trial (BRM421 Ophthalmic Solution, Vehicle)

Not yet recruiting
  • Dry Eye Disease
  • (no location specified)
Jan 13, 2023

Dry Eye Syndrome Trial in Andover (RGN-259, Placebo)

Completed
Has Results
  • Dry Eye Syndrome
  • Andover, Massachusetts
    Andover, MA
Dec 9, 2021

Myopia Trial in United States (Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic

Recruiting
  • Myopia
  • Atropine 0.1% Ophthalmic Solution
  • +2 more
  • Birmingham, Alabama
  • +18 more
Dec 14, 2021

Dry Eye Syndromes, Dry Eye Trial in United States (RGN-259, Placebo)

Completed
  • Dry Eye Syndromes
  • Dry Eye
  • Phoenix, Arizona
  • +19 more
May 2, 2022

Presbyopia Trial in United States (Pilocarpine Ophthalmic, Placebo)

Completed
  • Presbyopia
  • Pilocarpine Ophthalmic
  • Placebo
  • Azusa, California
  • +8 more
Aug 5, 2021

Keratoconjunctivitis Sicca, Dry Eye Trial in United States (tavilermide ophthalmic solution, Placebo)

Completed
  • Keratoconjunctivitis Sicca
  • Dry Eye
  • tavilermide ophthalmic solution
  • Placebo
  • Phoenix, Arizona
  • +21 more
Oct 18, 2021

Allergic Conjunctivitis Trial in Houston (Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle

Completed
  • Allergic Conjunctivitis
  • Reproxalap Ophthalmic Solution (0.25%)
  • +2 more
  • Houston, Texas
    Slade & Baker Vision
Dec 2, 2020

Conjunctivitis, Allergic Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%),

Completed
  • Conjunctivitis, Allergic
  • Reproxalap Ophthalmic Solution (0.25%)
  • +2 more
  • Mississauga, Ontario, Canada
    Inflamax Research Limited
May 11, 2020

Open Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (Travoprost Ophthalmic Topical Cream low-dose, Travoprost

Not yet recruiting
  • Open Angle Glaucoma
  • Ocular Hypertension
  • Travoprost Ophthalmic Topical Cream low-dose
  • +4 more
  • Newport Beach, California
    Glaukos Clinical Study Site
Nov 22, 2023

Neurotrophic Keratopathy Trial in United States (RGN-259, Placebo)

Terminated
  • Neurotrophic Keratopathy
  • Lancaster, California
  • +10 more
Jun 30, 2020

Healthy Adult Males Volunteers Trial in Osaka (STN1012600 ophthalmic solution 0.002%)

Recruiting
  • Healthy Adult Males Volunteers
  • STN1012600 ophthalmic solution 0.002%
  • Osaka, Japan
    Medical Corporation Heishinkai OPHAC Hospital
Jun 6, 2023

Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca Trial (5% Tavilermide ophthalmic solution, Vehicle ophthalmic

Not yet recruiting
  • Dry Eye Syndromes
  • +2 more
  • 5% Tavilermide ophthalmic solution
  • Vehicle ophthalmic solution
  • (no location specified)
Apr 27, 2023

Dry Eye Syndrome Trial in Andover (RGN-259, Placebo)

Completed
  • Dry Eye Syndrome
  • Andover, Massachusetts
    Andover, MA
Oct 7, 2019

Dry Eye Disease Trial in Andover (Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator)

Completed
  • Dry Eye Disease
  • Reproxalap Ophthalmic Solution (0.25%)
  • Placebo Comparator
  • Andover, Massachusetts
    Andover Eye Associates
Jan 24, 2023

Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035%

Not yet recruiting
  • Allergic Conjunctivitis
  • rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
  • Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
  • (no location specified)
Apr 4, 2023

Cataract, Glaucoma, Ocular Hypertension Trial in Glendale (Bimatoprost Implant System (High Dose), Bimatoprost Implant System

Recruiting
  • Cataract
  • +2 more
  • Bimatoprost Implant System (High Dose)
  • +4 more
  • Glendale, Arizona
    Arizona Advanced Eye Research Institute
Nov 8, 2023

Corneal Epithelial Degeneration Trial in Cypress (TTHX1114(NM141) Ophthalmic Solution)

Recruiting
  • Corneal Epithelial Degeneration
  • TTHX1114(NM141) Ophthalmic Solution
  • Cypress, California
    Trefoil Clinical Site #132
Mar 3, 2023

0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in

Not yet recruiting
  • Post Operative Endophthalmitis
  • Moxifloxacin hydrochloride ophthalmic solution
  • (no location specified)
Jan 11, 2023

Ocular Redness Trial in United States (Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify®

Recruiting
  • Ocular Redness
  • Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
  • Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
  • Colorado Springs, Colorado
  • +5 more
Oct 3, 2022

Dry Eye Trial in Mississauga (Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution))

Completed
  • Dry Eye
  • Reproxalap Ophthalmic Solution (0.25%)
  • Xiidra® (5% lifitegrast ophthalmic solution)
  • Mississauga, Ontario, Canada
    Cliantha Research
Sep 26, 2022

Opthalomology/Dry Eye Trial in Milan, Pisa (Irilens; Iridina; Afomill Lubricating Eye Drops)

Recruiting
  • Opthalomology/Dry Eye
  • Irilens; Iridina; Afomill Lubricating Eye Drops
  • Milan, Italy
  • +1 more
Mar 17, 2023

Rhegmatogenous Retinal Detachment - Macula Off Trial (ONL1204 Ophthalmic Solution, Sham treatment)

Not yet recruiting
  • Rhegmatogenous Retinal Detachment - Macula Off
  • ONL1204 Ophthalmic Solution
  • Sham treatment
  • (no location specified)
Feb 15, 2023